BG
ELOS

Baupost Group’s Syneron Medical Ltd ELOS Stock Holding History

Baupost Group’s Portfolio ELOS Stock Details ELOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-2,416,310
Closed -$22.5M – 29
2014
Q4 		$22.5M Sell
2,416,310
-578,300
-19% -$5.58M 0.44% 22
2014
Q3 		$30M Sell
2,994,610
-1,005,390
-25% -$10.2M 0.52% 19
2014
Q2 		$41.3M Hold
4,000,000
– – 0.67% 18
2014
Q1 		$49.8M Hold
4,000,000
– – 1.2% 15
2013
Q4 		$49.2M Hold
4,000,000
– – 1.39% 11
2013
Q3 		$34.5M Hold
4,000,000
– – 0.99% 11
2013
Q2 		$34.8M Buy
+4,000,000
New +$35.8M 0.87% 13

Other funds holding ELOS

SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
NTC
North Tide Capital Boston, Massachusetts $469M AUM 6.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
DGHMC
Dalton, Greiner, Hartman, Maher & Co New York $126M AUM 92.88% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Baupost Group's ELOS Position: Q1 2015 in Review

Baupost Group sold out of Syneron Medical Ltd (ELOS) in Q1 2015, closing a stake of 2,416,310 shares — an estimated $22.5M sold.

Baupost Group first reported a position in ELOS in Q2 2013 and held it in 7 quarters. The position peaked at $49.8M in Q1 2014. 80 funds tracked by Wall St. Rank hold ELOS as of Q1 2015.

  • Baupost Group reported no remaining Syneron Medical Ltd position as of Q1 2015 after selling out during the quarter.
  • Baupost Group sold 2,416,310 Syneron Medical Ltd shares in Q1 2015, an estimated $22.5M.
  • Baupost Group first reported a position in Syneron Medical Ltd in Q2 2013 and held it in 7 quarters.
  • Baupost Group's Syneron Medical Ltd position peaked at $49.8M in Q1 2014.
  • 80 funds tracked by Wall St. Rank held Syneron Medical Ltd as of Q1 2015.

Based on Baupost Group's 13F filing for Q1 2015, filed 15 May 2015.